BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34593524)

  • 21. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
    Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
    Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.
    Guzman ML; Rossi RM; Karnischky L; Li X; Peterson DR; Howard DS; Jordan CT
    Blood; 2005 Jun; 105(11):4163-9. PubMed ID: 15687234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
    Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
    Kruczynski A; Pillon A; Créancier L; Vandenberghe I; Gomes B; Brel V; Fournier E; Annereau JP; Currie E; Guminski Y; Bonnet D; Bailly C; Guilbaud N
    Leukemia; 2013 Nov; 27(11):2139-48. PubMed ID: 23568148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2.
    Hedley DW; McCulloch EA
    Leukemia; 1996 Jul; 10(7):1143-9. PubMed ID: 8683994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
    Kawabata KC; Zong H; Meydan C; Wyman S; Wouters BJ; Sugita M; Goswami S; Albert M; Yip W; Roboz GJ; Chen Z; Delwel R; Carroll M; Mason CE; Melnick A; Guzman ML
    Blood; 2021 Feb; 137(6):812-825. PubMed ID: 32911532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.
    Strese S; Hassan SB; Velander E; Haglund C; Höglund M; Larsson R; Gullbo J
    Oncotarget; 2017 Jan; 8(4):6341-6352. PubMed ID: 27974676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-aminoimidazole-4-carboxamide ribonucleoside induces differentiation in a subset of primary acute myeloid leukemia blasts.
    Dembitz V; Lalic H; Kodvanj I; Tomic B; Batinic J; Dubravcic K; Batinic D; Bedalov A; Visnjic D
    BMC Cancer; 2020 Nov; 20(1):1090. PubMed ID: 33176741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitotic MTH1 Inhibitors in Treatment of Cancer.
    Helleday T
    Cancer Treat Res; 2023; 186():223-237. PubMed ID: 37978139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
    Dos Santos C; McDonald T; Ho YW; Liu H; Lin A; Forman SJ; Kuo YH; Bhatia R
    Blood; 2013 Sep; 122(11):1900-13. PubMed ID: 23896410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
    Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
    Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
    Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
    Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD97 is a critical regulator of acute myeloid leukemia stem cell function.
    Martin GH; Roy N; Chakraborty S; Desrichard A; Chung SS; Woolthuis CM; Hu W; Berezniuk I; Garrett-Bakelman FE; Hamann J; Devlin SM; Chan TA; Park CY
    J Exp Med; 2019 Oct; 216(10):2362-2377. PubMed ID: 31371381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
    Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
    Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
    Khalife J; Radomska HS; Santhanam R; Huang X; Neviani P; Saultz J; Wang H; Wu YZ; Alachkar H; Anghelina M; Dorrance A; Curfman J; Bloomfield CD; Medeiros BC; Perrotti D; Lee LJ; Lee RJ; Caligiuri MA; Pichiorri F; Croce CM; Garzon R; Guzman ML; Mendler JH; Marcucci G
    Leukemia; 2015 Oct; 29(10):1981-92. PubMed ID: 25971362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways.
    Pulikkottil AJ; Bamezai S; Ammer T; Mohr F; Feder K; Vegi NM; Mandal T; Kohlhofer U; Quintanilla-Martinez L; Sinha A; Buske C; Rawat VPS
    Leukemia; 2022 Feb; 36(2):416-425. PubMed ID: 34462525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia.
    Hosseini M; Rezvani HR; Aroua N; Bosc C; Farge T; Saland E; Guyonnet-Dupérat V; Zaghdoudi S; Jarrou L; Larrue C; Sabatier M; Mouchel PL; Gotanègre M; Piechaczyk M; Bossis G; Récher C; Sarry JE
    Cancer Res; 2019 Oct; 79(20):5191-5203. PubMed ID: 31358527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.